Загрузка...
Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome
PURPOSE: Teduglutide, a glucagon-like peptide-2 analog, has demonstrated efficacy in reducing parenteral support (PS) among patients with short bowel syndrome with intestinal failure (SBS–IF). This study aims to identify a subpopulation of SBS–IF patients for whom teduglutide has an especially prono...
Сохранить в:
| Опубликовано в: : | Ther Clin Risk Manag |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6065551/ https://ncbi.nlm.nih.gov/pubmed/30100725 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S166081 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|